メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
地引 綾
薬学科
ウェブサイト
https://k-ris.keio.ac.jp/html/100012957_ja.html
h-index
61
被引用数
5
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2017
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(14)
類似のプロファイル
(6)
フィンガープリント
Aya Jibikiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Azathioprine
100%
Rheumatoid Arthritis
100%
Non Small Cell Lung Cancer
100%
Cefmetazole
100%
Observational Study
74%
Retrospective Study
56%
Dacomitinib
50%
Osimertinib
50%
Bosutinib
50%
Active Metabolite
50%
Pharmacokinetics
50%
Carbon
50%
Pembrolizumab
50%
Adverse Event
50%
Carbon 11
50%
Nilotinib
50%
Pharmaceutics
50%
Dasatinib
50%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
50%
Nivolumab
50%
Carbon 13
50%
Protein Tyrosine Kinase Inhibitor
50%
Carbon 14
50%
Ingenol Mebutate
50%
Ponatinib
50%
Pharmacogenomics
50%
Infliximab
50%
Penicillinase
50%
Urinary Tract Infection
50%
Escherichia coli
50%
Inosine
43%
Overall Survival
30%
High Performance Liquid Chromatography
28%
Chronic Myeloid Leukemia
21%
Malignant Neoplasm
20%
Progression Free Survival
20%
Methotrexate
16%
Minimum Inhibitory Concentration
16%
Recurrence Risk
16%
Therapeutic Drug Monitoring
13%
ABCG2
12%
Disease Activity Score
12%
Epidermal Growth Factor Receptor
12%
Systemic Lupus Erythematosus
12%
Multidrug Resistance Associated Protein 4
12%
Asenapine
11%
Roseburia
10%
Mortality Rate
8%
Clinical Trial
8%
Drug
7%
Keyphrases
Antibodies to Infliximab
50%
Antibody Level
50%
Pembrolizumab
50%
Prognostic Value
50%
Rheumatoid Arthritis
50%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
50%
Nivolumab
50%
ESBL-E
50%
Successful Experience
50%
Enactive
50%
Pharmacy Practice Experience
50%
Neutrophil-to-lymphocyte Ratio
50%
Anti-infliximab Antibodies
50%
Ingenol Mebutate
50%
Pica Behavior
50%
Boiogito
50%
Prognostic Score
33%
Infliximab
30%
Methotrexate
30%
Overall Survival
25%
Bofutsushosan
25%
AZ5104
20%
Survival Outcomes
16%
Cox Proportional Hazards Model
16%
Progression-free Survival
16%
NUDT15
14%
Method Calibration
10%
Protein Precipitation Method
10%
Normalized Matrix
10%
Serum Antibody
10%
Japanese Adults
10%
Rheumatoid Arthritis Treatment
10%
Adult Patients
10%
Limit of Quantification
10%
Concomitant Use
10%
Serum Concentration
10%
Expiry
9%
Retrospective Observational Study
8%
Poor Outcome
8%
Clinical Outcomes
8%
Inflammatory Index
8%
Japan
8%
Consecutive Patients
8%
Group-level Outcome
8%
Stratified Group
8%
Poor Prognosis
8%
Multivariable
8%
Confidence Interval
8%
Concomitant Medications
8%
Regression Coefficient
8%
Immunology and Microbiology
Inflammatory Arthritis
100%
Azathioprine
100%
Lipid Storage
50%
White Adipose Tissue
50%
Infliximab
50%
High Performance Liquid Chromatography
50%
Genetic Polymorphism
50%
Mouse Model
50%
Intestine Flora
50%
Myeloid
37%
Monospecific Antibody
22%
Total Cholesterol Level
20%
Body Fat
20%
Methotrexate
16%
Liquid Chromatography Tandem Mass Spectrometry
12%
Dilution
12%
Serum (Blood)
12%
Low Drug Dose
12%
Solid Phase Extraction
12%
Systemic Lupus Erythematosus
12%
Roseburia
10%
Body Weight
10%
Body Weight Gain
10%
Triacylglycerol Level
10%
C57BL 6 Mouse
10%
Triacylglycerol Blood Level
10%
Clostridium
10%
Lachnospiraceae
10%
Maintenance Drug Dose
6%
Inflammatory Bowel Disease
6%
Blood Level
5%
Antibody Blood Level
5%
